Mendus announces positive data from the ALISON trial in ovar

VIDIDENCEL INDUCES DURABLE VACCINE-INDUCED T-CELL RESPONSES IN THE MAJORITY OF PATIENTS Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today... | April 19, 2023

Related Keywords

Netherlands , Groningen , Sweden , United States , Stockholm , American , Corey Davis , Erik Manting , Mario Brkulj , American Association For Cancer Research , University Medical Center Groningen , Lifesci Advisors , Valency Communications , Department Of Obstetrics , American Association , Cancer Research , Annual Meeting , Immunomodulatory Agents , Interventions Session , High Grade Serous Ovarian Cancer , Nasdaq Stockholm , Sci Advisors , Mendus Ab Publ Stock Exchange , News , Information , Press Release , Ididencel , Induces , Durable , Responses , N , The , Majority , F , Patients , Mendus , Tb , Iopharmaceutical , Company , Ocused , Mmunotherapies , Ddressing , Umor Immu Se0005003654 ,